Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895782917> ?p ?o ?g. }
- W2895782917 endingPage "17" @default.
- W2895782917 startingPage "8" @default.
- W2895782917 abstract "Metastatic or advanced breast cancer (mBC/ABC) remains incurable despite many different systemic treatment options. Hormone receptor positive (HR+) disease represents the most common subtype in both early and advanced disease. A better understanding of the biology of this BC subtype, in particular regarding potential mechanisms of endocrine resistance, has led to the development of CDK4/6 inhibitors. All three selective CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib have shown to significantly improve progression-free survival (PFS) when combined to endocrine therapy as first-line treatment for patients with HR+/HER-2 negative ABC, who have progressed on or after adjuvant endocrine therapy. All three of them have also shown an improved PFS as 2nd line therapy for HR+/Her2 negative ABC. Their toxicity profile is favorable, with hematological toxicity (mainly neutropenia) being predominant, followed by diarrhea and fatigue. Quality of life has been maintained in the 1st line setting or improved in the 2nd line setting. Overall survival (OS) has been reported so far only in 2 out of 7 trials as first line therapy and the difference did not reach statistical significance. In this article we review the biology of CDK signaling pathway and its inhibitors, preclinical and clinical data of all three investigated selective CDK4/6 inhibitors and their toxicity. We also discuss how these agents are being included in current international guidelines and future directions for these agents in other subtypes of breast cancer, in both advanced disease and early-stage disease." @default.
- W2895782917 created "2018-10-26" @default.
- W2895782917 creator A5016725149 @default.
- W2895782917 creator A5025554206 @default.
- W2895782917 creator A5081823264 @default.
- W2895782917 date "2019-02-01" @default.
- W2895782917 modified "2023-10-18" @default.
- W2895782917 title "Targeting CDK4/6 pathways and beyond in breast cancer" @default.
- W2895782917 cites W1464936406 @default.
- W2895782917 cites W1525531613 @default.
- W2895782917 cites W1527674890 @default.
- W2895782917 cites W1967891134 @default.
- W2895782917 cites W1975570973 @default.
- W2895782917 cites W1982166284 @default.
- W2895782917 cites W1984245506 @default.
- W2895782917 cites W1984252723 @default.
- W2895782917 cites W1991601194 @default.
- W2895782917 cites W1998040747 @default.
- W2895782917 cites W2001997645 @default.
- W2895782917 cites W2004000621 @default.
- W2895782917 cites W2006262026 @default.
- W2895782917 cites W2019695814 @default.
- W2895782917 cites W2029080338 @default.
- W2895782917 cites W2033672070 @default.
- W2895782917 cites W2036735691 @default.
- W2895782917 cites W2043761487 @default.
- W2895782917 cites W2066848701 @default.
- W2895782917 cites W2067873262 @default.
- W2895782917 cites W2075731214 @default.
- W2895782917 cites W2096283457 @default.
- W2895782917 cites W2096979580 @default.
- W2895782917 cites W2117357260 @default.
- W2895782917 cites W2129036353 @default.
- W2895782917 cites W2131017274 @default.
- W2895782917 cites W2132726386 @default.
- W2895782917 cites W2133382697 @default.
- W2895782917 cites W2136158663 @default.
- W2895782917 cites W2137177885 @default.
- W2895782917 cites W2139132031 @default.
- W2895782917 cites W2141393790 @default.
- W2895782917 cites W2144790402 @default.
- W2895782917 cites W2148345265 @default.
- W2895782917 cites W2154626333 @default.
- W2895782917 cites W2157803976 @default.
- W2895782917 cites W2166517176 @default.
- W2895782917 cites W2290950904 @default.
- W2895782917 cites W2291124025 @default.
- W2895782917 cites W2295971206 @default.
- W2895782917 cites W2299045691 @default.
- W2895782917 cites W2309969893 @default.
- W2895782917 cites W2313479654 @default.
- W2895782917 cites W2404884142 @default.
- W2895782917 cites W2464376480 @default.
- W2895782917 cites W2474228968 @default.
- W2895782917 cites W2474699717 @default.
- W2895782917 cites W2479570008 @default.
- W2895782917 cites W2493204726 @default.
- W2895782917 cites W2514862430 @default.
- W2895782917 cites W2528767298 @default.
- W2895782917 cites W2552099557 @default.
- W2895782917 cites W2587481440 @default.
- W2895782917 cites W2588439324 @default.
- W2895782917 cites W2590301302 @default.
- W2895782917 cites W2612124029 @default.
- W2895782917 cites W2617437931 @default.
- W2895782917 cites W2620993107 @default.
- W2895782917 cites W2622040450 @default.
- W2895782917 cites W2678824027 @default.
- W2895782917 cites W2750328162 @default.
- W2895782917 cites W2753603515 @default.
- W2895782917 cites W2763349137 @default.
- W2895782917 cites W2763742548 @default.
- W2895782917 cites W2782896696 @default.
- W2895782917 cites W2789574985 @default.
- W2895782917 cites W2802776309 @default.
- W2895782917 cites W2804105316 @default.
- W2895782917 cites W2807927321 @default.
- W2895782917 cites W4239051461 @default.
- W2895782917 doi "https://doi.org/10.1016/j.breast.2018.10.001" @default.
- W2895782917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30359883" @default.
- W2895782917 hasPublicationYear "2019" @default.
- W2895782917 type Work @default.
- W2895782917 sameAs 2895782917 @default.
- W2895782917 citedByCount "20" @default.
- W2895782917 countsByYear W28957829172019 @default.
- W2895782917 countsByYear W28957829172020 @default.
- W2895782917 countsByYear W28957829172021 @default.
- W2895782917 countsByYear W28957829172022 @default.
- W2895782917 countsByYear W28957829172023 @default.
- W2895782917 crossrefType "journal-article" @default.
- W2895782917 hasAuthorship W2895782917A5016725149 @default.
- W2895782917 hasAuthorship W2895782917A5025554206 @default.
- W2895782917 hasAuthorship W2895782917A5081823264 @default.
- W2895782917 hasConcept C121608353 @default.
- W2895782917 hasConcept C126322002 @default.
- W2895782917 hasConcept C143998085 @default.
- W2895782917 hasConcept C2775930923 @default.
- W2895782917 hasConcept C2777063308 @default.